Evidence map›Paper›PMID 39461776›Full record

ArticleESMO open2024

Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].

I Hartlapp, D Valta-Seufzer, J T Siveke, H Algül, E Goekkurt, G Siegler, U M Martens, D Waldschmidt, U Pelzer, M Fuchs and 12 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Study of serum tumor markers in the early diagnosis of pancreatic cancer.World journal of gastrointestinal oncology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors.

I HartlappDepartment of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg.
D Valta-SeufzerDepartment of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg.
J T SivekeDepartment of Medical Oncology, Bridge Institute of Experimental Tumor Therapy, University Medicine Essen, Essen; Division of Solid Tumor Translational Oncology (DKTK Partner Site Essen, DKFZ Heidelberg), West German Cancer Center, University Medicine Essen, Essen.
H AlgülComprehensive Cancer Center München, Institute for Tumor Metabolism, Klinikum rechts der Isar, Technical University of Munich, School of Medicine and Health, Munich, Bavaria, Germany.
E GoekkurtHämatologisch-Onkologische Praxis Eppendorf (HOPE), Hamburg and University Cancer Center Hamburg (UCCH), Hamburg, Germany.
G SieglerDepartment of Internal Medicine 5, Hematology and Medical Oncology, Paracelsus Medical University, Nürnberg.
U M MartensDepartment of Internal Medicine III, SLK-Clinics Heilbronn GmbH, Heilbronn.
D WaldschmidtDepartment of Gastroenterology and Hepatology, University Hospital Cologne, Cologne.
U PelzerDivision of Oncology and Hematology, Charité Campus Mitte, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin.
M FuchsClinic for Gastroenterology, Hepatology and GI-Oncology, München Klinik Bogenhausen, Munich.
F KullmannDepartment of Internal Medicine I, Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden.
S BoeckDepartment of Medical Oncology and Comprehensive Cancer Center, Ludwig Maximilians University-Grosshadern, Munich.
T J EttrichDepartment of Internal Medicine I, Ulm University Hospital, Ulm.
S HeldDepartment of Biometrics, ClinAssess GmbH, Leverkusen.
R KellerClinical Research, AIO Studien gGmbH, Berlin.
F AngerDepartment of General, Visceral, Transplantation, Vascular and Pediatric Surgery and Comprehensive Cancer Center Mainfranken Würzburg, University Hospital Würzburg, Würzburg.
C T GermerDepartment of General, Visceral, Transplantation, Vascular and Pediatric Surgery and Comprehensive Cancer Center Mainfranken Würzburg, University Hospital Würzburg, Würzburg.
A StangDepartment of Haematology, Oncology and Palliative Care Medicine, Asklepios Hospital Barmbek, Hamburg, Germany.
B KimmelDepartment of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg.
V HeinemannDepartment of Medical Oncology and Comprehensive Cancer Center, Ludwig Maximilians University-Grosshadern, Munich.
V KunzmannDepartment of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg. Electronic address: kunzmann_v@ukw.de.
German Pancreatic Cancer Group (AIO-PAK) and NEOLAP investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39461776
PMCPMC11549499

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.